Expanded Access to Epcoritamab
- Conditions
- Lymphoma
- Registration Number
- NCT05692050
- Lead Sponsor
- AbbVie
- Brief Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to epcoritamab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- The participant must not be eligible for an epcoritamab clinical trial.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are epcoritamab's (AbbVie) molecular mechanisms targeting CD20 and CD3 in B-cell lymphoma treatment?
How does epcoritamab's efficacy in EAP compare to standard chemoimmunotherapy for B-cell lymphoma?
Which biomarkers predict epcoritamab response in CD20-positive lymphoma patients via AbbVie's EAP?
What adverse events occur with epcoritamab in lymphoma EAPs and their management strategies?
What combination therapies with epcoritamab (AbbVie) are explored for lymphoma vs. other CD20 agents?